Seres Therapeutics (NASDAQ:MCRB) Raised to Hold at StockNews.com
Seres Therapeutics (NASDAQ:MCRB – Get Free Report) was upgraded by StockNews.com from a “sell” rating to a “hold” rating in a research report issued to clients and investors on Friday. Other equities analysts also recently issued research reports about the stock. Chardan Capital reiterated a “buy” rating and set a $1.25 target price on shares […]
More Stories
Lake Street Capital Begins Coverage on Anteris Technologies Global (NASDAQ:AVR)
Analysts at Lake Street Capital began coverage on shares of Anteris Technologies Global (NASDAQ:AVR – Get Free Report) in a...
Relx (NYSE:RELX) Now Covered by Analysts at Redburn Atlantic
Investment analysts at Redburn Atlantic assumed coverage on shares of Relx (NYSE:RELX – Get Free Report) in a research note...
Texas Roadhouse (NASDAQ:TXRH) Rating Lowered to “Hold” at Gordon Haskett
Texas Roadhouse (NASDAQ:TXRH – Get Free Report) was downgraded by analysts at Gordon Haskett from a “buy” rating to a...
The Toronto-Dominion Bank (TD) to Issue Quarterly Dividend of $1.05 on January 31st
The Toronto-Dominion Bank (TSE:TD – Get Free Report) (NYSE:TD) announced a quarterly dividend on Friday, January 10th,TickerTech Dividends reports. Investors...
West Pharmaceutical Services (NYSE:WST) Coverage Initiated by Analysts at Citigroup
Analysts at Citigroup assumed coverage on shares of West Pharmaceutical Services (NYSE:WST – Get Free Report) in a research note...
AngioDynamics (NASDAQ:ANGO) Updates FY 2025 Earnings Guidance
AngioDynamics (NASDAQ:ANGO – Get Free Report) updated its FY 2025 earnings guidance on Wednesday. The company provided earnings per share...